[1] Hu M-H, Wu T-Y, Huang Q, Jin Guangyi. New substituted quinoxalines inhibit triple-negative breast cancer by specifically downregulating the c-MYC transcription[J]. Nucleic acids research.2019; doi:10.1093/nar/gkz835.
[2] Zagorac I, Fernandez-Gaitero S, Penning R, Post H, Bueno M J, Mouron S, et al. In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer[J]. Nature communications. 2018; doi:10.1038/s41467-018-05742-z.
[3] Sikov W M, Berry D A, Perou C M, Singh B, T Cirrincione C, Tolaney S M, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)[J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2015; doi:10.1200/JCO.2014.57.0572.
[4] Dushyanthen S, Teo Z L, Caramia F, Savas P, Mintoff C P, Virassamy B, et al. Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer[J]. Nature communications. 2017; doi:10.1038/s41467-017-00728-9.
[5] Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014[J]. Annals of oncology: official journal of the European Society for Medical Oncology. 2015; doi:10.1093/annonc/mdu450.
[6] Pujani M, Jain H, Chauhan V, Agarwal C, Singh K, Singh M. Evaluation of Tumor infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage[J]. Breast disease. 2020; doi:10.3233/BD-200442.
[7] Callaghan M J, Russell A J, Woollatt E, Sutherland G R, Sutherland R L, Watts C K. Identification of a human HECT family protein with homology to the Drosophila tumor suppressor gene hyperplastic discs[J]. Oncogene. 1998; doi:10.1038/sj.onc.1202249.
[8] Henderson M J, Russell A J, Hird S, Muñoz M, Clancy J L, Lehrbach G M. EDD, the human hyperplastic discs protein, has a role in progesterone receptor coactivation and potential involvement in DNA damage response[J]. The Journal of biological chemistry. 2002; doi:10.1074/jbc.M203527200.
[9] Henderson M J, Munoz M A, Saunders D N, Clancy J L, Russell A J, Williams B, et al. EDD mediates DNA damage-induced activation of CHK2[J]. The Journal of biological chemistry. 2006; doi:10.1074/jbc.M602818200.
[10] Brotin E, Meryet-Figuiere M, Simonin K, Duval R E, Villedieu M, Leroy-Dudal J, et al. Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis[J]. International journal of cancer. 2010; doi:10.1002/ijc.24787.
[11] Shearer R F, Iconomou M, Watts C K W, Saunders D N. Functional Roles of the E3 Ubiquitin Ligase UBR5 in Cancer[J]. Molecular cancer research: MCR. 2015; doi:10.1158/1541-7786.MCR-15-0383.
[12] Qiao X, Liu Y, Prada M L, Mohan A K, Gupta A, Jaiswal A, et al. UBR5 Is Coamplified with MYC in Breast Tumors and Encodes an Ubiquitin Ligase That Limits MYC-Dependent Apoptosis[J]. Cancer research. 2020; doi:10.1158/0008-5472.CAN-19-1647.
[13] Chen L, Yuan R, Wen C, Liu T, Feng Q, Deng X, et al. E3 ubiquitin ligase UBR5 promotes pancreatic cancer growth and aerobic glycolysis by downregulating FBP1 via destabilization of C/EBPα[J]. Oncogene. 2020; doi:10.1038/s41388-020-01527-1.
[14] Song M, Wang C, Wang H, Zhang T, Li J, Benezra R, et al. Targeting ubiquitin protein ligase E3 component N-recognin 5 in cancer cells induces a CD8+ T cell mediated immune response[J]. Oncoimmunology. 2020; doi:10.1080/2162402X.2020.1746148.
[15] Loi S, Drubay D, Adams S, Pruneri G, Francis P A, Lacroix-Triki M, et al. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers[J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2019; doi:10.1200/JCO.18.01010.
[16] Tian T, Ruan M, Yang W, Shui R. Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers[J]. Oncotarget. 2016; doi:10.18632/oncotarget.10054.
[17] Carbognin L, Pitotto S, Nortilli R, Brunelli M, Nottegar A, Sperduti I, et al. Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting[J]. The oncologist. 2016; doi:10.1634/theoncologist.2015-0307.
[18] Aierken N, Shi H-J, Zhou Y, Shao N, Zhang J, Shi Y, et al. High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients[J]. International journal of biological sciences. 2017; doi:10.7150/ijbs.20868.
[19] O'loughlin M, Andreu X, Bianchi S, Chemielik E, Cordoba A, Cserni G, et al. Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study[J]. Breast cancer research and treatment. 2018; doi:10.1007/s10549-018-4825-8.
[20] Ruan M, Tian T, Rao J, Xu X, Yu B, Yang W, et al. Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers[J]. Diagnostic pathology. 2018; doi:10.1186/s13000-018-0743-7.
[21] Schmid P, Salgado R, Park Y H, Muñoz-Couselo E, Kim S B, Sohn J, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study[J]. Annals of oncology: official journal of the European Society for Medical Oncology. 2020; doi:10.1016/j.annonc.2020.01.072.
[22] Eryil Maz M K, Mutlu H, ÜNAL B, Salim D K, Musri F Y, Coşkun H S. The importance of stromal and intratumoral tumor lymphocyte infiltration for pathologic complete response in patients with locally advanced breast cancer[J]. Journal of cancer research and therapeutics. 2018; doi:10.4103/0973-1482.174550.
[23] Chae H, Yoo C, Yoon J-A, Lee H J, Kim K-P, Kim J-E, et al. FcrR3A-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment[J]. Journal of breast cancer. 2018; doi:10.4048/jbc.2018.21.1.45.
[24] Yang X, Rao J, Yang W, Shui R. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy[J]. Targeted oncology. 2018; doi:10.1007/s11523-018-0602-1.
[25] Liu J, Xu Y, Yu M, Liu Z, Xu Y, Ma G, et al. Increased Stromal Infiltrating Lymphocytes are Associated with Circulating Tumor Cells and Metastatic Relapse in Breast Cancer Patients After Neoadjuvant Chemotherapy[J]. Cancer management and research. 2019; doi:10.2147/CMAR.S220327.
[26] Zhang Z, Zheng X, Li J, Duan J, Cui L, Yang L, et al. Overexpression of UBR5 promotes tumor growth in gallbladder cancer via PTEN/PI3K/Akt signal pathway[J]. Journal of cellular biochemistry. 2019; doi:10.1002/jcb.28431.
[27] Wang K, Tang J, Liu X, Wang Y, Chen W, Zheng R. UBR5 regulates proliferation and radiosensitivity in human laryngeal carcinoma via the p38/MAPK signaling pathway[J]. Oncology reports. 2020; doi:10.3892/or.2020.7620.
[28] Saurabh K, Shah P P, Doll M A, Siskind L J, Beverly L J. UBR-box containing protein, UBR5, is over-expressed in human lung adenocarcinoma and is a potential therapeutic target[J]. BMC cancer. 2020; doi: 10.1186/s12885-020-07322-1.
[29] Ding F, Zhu X, Song X, Yuan P, Ren L, Chai C, et al. UBR5 oncogene as an indicator of poor prognosis in gastric cancer[J]. Experimental and therapeutic medicine. 2020; doi:10.3892/etm.2020.9135.
[30] Yang M, Jiang N, Cao Q-W, Ma M-Q, Sun Q. The E3 ligase UBR5 regulates gastric cancer cell growth by destabilizing the tumor suppressor GKN1[J]. Biochemical and biophysical research communications. 2016; doi:10.1016/j.bbrc.2016.08.170.
[31] Wang J, Zhao X, Jin L, Wu G, Yang Y. UBR5 Contributes to Colorectal Cancer Progression by Destabilizing the Tumor Suppressor ECRG4[J]. Digestive diseases and sciences. 2017; doi:10.1007/s10620-017-4732-6.
[32] Xie Z, Liang H, Wang J, Xu X, Zhu Y, Guo A, et al. Significance of the E3 ubiquitin protein UBR5 as an oncogene and a prognostic biomarker in colorectal cancer[J]. Oncotarget. 2017; doi:10.18632/oncotarget.22531.
[33] Ji S Q, Zhang Y X, Yang B H. UBR5 promotes cell proliferation and inhibits apoptosis in colon cancer by destablizing P21[J]. Die Pharmazie. 2017; doi:10.1691/ph.2017.7433.
[34] Yang Y, Zhao J, Mao Y, Li F, Jiang Z. UBR5 over-expression contributes to poor prognosis and tamoxifen resistance of ERa+ breast cancer by stabilizing β-catenin[J]. Breast cancer research and treatment. 2020; doi:10.1007/s10549-020-05899-6.
[35] Bian P, Dou Z, Jia Z, Li W, Pan D. Activated Wnt/β-Catenin signaling contributes to E3 ubiquitin ligase EDD-conferred docetaxel resistance in prostate cancer[J]. Life sciences. 2020; doi:10.1016/j.lfs.2019.116816.
[36] Matsuura K, Huang N-J, Cocce K, Zhang L, Kornbluth S. Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin[J]. Oncogene. 2017; doi:10.1038/onc.2016.336.
[37] Liao L, Song M, Li X, Tang L, Zhang T, Zhang L, et al. E3 Ubiquitin Ligase UBR5 Drives the Growth and Metastasis of Triple-Negative Breast Cancer[J]. Cancer research. 2017; doi:10.1158/0008-5472.CAN-16-2409.